Year-end Sale % OFF 
Abstract
SUMMARY Panobinostat is a deacetylase inhibitor that exerts antitumor activity by modifying the acetylation status of histones and other critical cellular proteins. Panobinostat as a single agent produced an overall response rate of 27% in patients with relapsed or recurrent Hodgkin lymphoma after stem cell transplantation. Clinical trials of panobinostat combined with chemotherapy or with other targeting agents such as mTOR inhibitors or lenalidomide have shown promising interim results. The most common toxicity with panobinostat as a single agent or in combination is thrombocytopenia. Patient enrollment in ongoing or future clinical trials of panobinostat is encouraged so that the role of this agent in patients with recurrent classical Hodgkin lymphoma can be further studied.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
